The Keytruda Cliff and the $70B Pivot — Understanding Merck's Most Important Decade

Every Merck candidate in 2026 should walk into the room knowing exactly what "the Keytruda cliff" means and what the company is doing about it. This module covers the 2028 patent loss, the $35B peak, the QLEX subcutaneous formulation, and CEO Rob Davis's $70B revenue ambition for the mid-2030s — strategic context that lets you answer "where do you see yourself fitting in?" with real substance.